Search results for "Alcoholic"

showing 10 items of 509 documents

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

2016

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyCirrhosisDiseaseGastroenterologyLiver diseaseNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansGeneral Environmental Sciencebusiness.industryGeneral EngineeringArteriosclerosismedicine.diseaseAtherosclerosisdigestive system diseasesCardiovascular DiseasesDisease ProgressionGeneral Earth and Planetary SciencesSteatosisSteatohepatitisLiver cancerbusinessClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
researchProduct

Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.

2016

NAFLD (Non-Alcoholic Fatty Liver Disease) is an increasingly significant public health issue, regarded as the most relevant liver disease of the twenty-first century. Approximately 20%-30% of NAFLD subjects develop a NASH (Non-Alcoholic Steato-Hepatitis), a condition which can potentially evolve to liver cirrhosis and hepatocellular carcinoma. For these reasons a proper evaluation of liver damage is a key point for diagnosis and prognosis and liver biopsy still remains the "gold standard" procedure both for discrimination between steatosis and steatohepatitis and assessment of the degree of liver fibrosis. Nonetheless, given it is an invasive, painful and costly procedure, a great research …

medicine.medical_specialtyCirrhosisFibrosiBiopsyClinical Decision-MakingApoptosis030204 cardiovascular system & hematologyBiochemistryGastroenterologyMultimodal Imaging03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineAnimalsHumansMortalityMolecular BiologyLiver injurymedicine.diagnostic_testAnimalbusiness.industryFatty liverApoptosiBiomarkerGeneral Medicinemedicine.diseasePrognosisFibrosisdigestive system diseasesAlgorithmLiverLiver biopsyHepatocellular carcinomaMolecular Medicine030211 gastroenterology & hepatologySteatosisSteatohepatitisMorbiditybusinessAlgorithmsBiomarkersHumanCurrent molecular medicine
researchProduct

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation

2019

Background & Aims Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL. Methods We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection. Results The mean CLDQ overall score was 5.0 ± 1.2, with the lowest score in the category fatigue (4.3 ± 1.6) and the highest scores for activity (5.4 ± 1.4). …

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologymedicine.diseaseChronic liver diseaseGastroenterology3. Good health03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPatient-reported outcomebusinessBody mass indexClinical Gastroenterology and Hepatology
researchProduct

A Cholestatic Pattern Predicts Liver-Related Events in Patients with Nonalcoholic Fatty Liver Disease

2021

Background & Aims: Liver test alteration patterns can be categorized as: predominantly hepatocellular(H), with an ALT/ALP ratio>5; predominantly cholestatic pattern(C) with a ratio 55 years(HR2.55,95%C.I.1.17-5.54;p=0.01), platelets<150,000/mmc(HR0.14,95%C.I.0.06-0.32;p<0.001), albumin<4g/L(HR0.62,95%C.I.0.35-1.08;p=0.09), C vs M pattern(HR7.86,95%C.I.1.03-60.1;p=0.04), C vs H pattern(HR12.1,95% C.I.1.61-90.9;p=0.01) and fibrosis F3-F4(HR35.8,95%C.I.4.65-275.2;p<0.001) were independent risk factors for LRE occurrence. C vs M pattern(HR14.3,95%C.I.1.90-105.6;p=0.008) and C vs H pattern(HR15.6,95%C.I. 2.10-115.1;p=0.0068) were confirmed independently associated with LRE occurrence in the vali…

medicine.medical_specialtyCirrhosisbusiness.industryProportional hazards modelmedicine.diseaseGastroenterologyLiver diseaseCholestasisMetaplasiaInternal medicineCohortNonalcoholic fatty liver diseaseMedicineIn patientmedicine.symptombusinessSSRN Electronic Journal
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

A New Score Unveils a High Prevalence of Mild Cognitive Impairment in Patients with Nonalcoholic Fatty Liver Disease

2021

Patients with nonalcoholic fatty liver disease (NAFLD) may show mild cognitive impairment (MCI). The neurological functions affected remain unclear. The aims were to: (1) Characterize the neuropsychological alterations in NAFLD patients; (2) assess the prevalence of impairment of neurological functions evaluated; (3) develop a new score for sensitive and rapid MCI detection in NAFLD; (4) assess differences in MCI features between patients with nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH); and (5) compare neuropsychological alterations in NAFLD patients with cirrhotic patients with MCI. Fifty-nine NAFLD patients and 53 controls performed psychometric tests assessin…

medicine.medical_specialtyCirrhosisneurological impairmentpsychometric scoreGastroenterologybehavioral disciplines and activitiesdigestive systemArticle03 medical and health sciences0302 clinical medicineInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineMemory spanHepatic encephalopathyPsychomotor learningbusiness.industryFatty liverRNeuropsychologyNASHnutritional and metabolic diseasesGeneral Medicinemedicine.diseasepsychometric score; NAFLD; NAFL; NASH; neurological impairmentdigestive system diseasesNAFLMedicine030211 gastroenterology & hepatologybusiness030217 neurology & neurosurgeryStroop effectJournal of Clinical Medicine
researchProduct

Advancing the global public health agenda for NAFLD: a consensus statement

2021

Digital

medicine.medical_specialtyCivil societyDelphi methodMEDLINENashMULTIDISCIPLINARY APPROACHDiseaseLATIN-AMERICAN ASSOCIATIONMultidisciplinary approachQUALITY-OF-LIFENon-alcoholic Fatty Liver DiseaseEpidemiologyMedicineHumansHumans; Non-alcoholic Fatty Liver DiseasePOSITION STATEMENTBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.FATTY LIVER-DISEASEBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Hepatologybusiness.industryPublic healthGastroenterologyALCOHOLIC STEATOHEPATITISNONINVASIVE DIAGNOSISmedicine.diseaseObesityCARDIOVASCULAR-DISEASEPRACTICE GUIDELINESFamily medicinePRACTICAL APPROACHHuman medicinebusiness
researchProduct

Recent advances on stearoyl-Coa desaturase regulation in fatty liver diseases.

2012

Stearoyl-CoA desaturase 1 (SCD-1) is a delta-9 fatty acid desaturase that catalyzes the synthesis of monounsaturated fatty acids. Indeed, SCD-1 is the critical control point regulating hepatic lipogenesis and lipid oxidation. Due to its central role in lipid metabolism in the liver, recent studies have focused on the involvement of SCD-1 in the development of fatty liver during obesity, diabetes mellitus, hypertension, excessive alcohol consumption, and in subjects with high triglyceride blood concentrations. The accumulation of fat in liver cells can be a sign that harmful conditions are developing, possibly associated with or leading to inflammation of the liver. This review evaluates the…

medicine.medical_specialtyClinical Biochemistrychemistry.chemical_compoundLipid oxidationInternal medicineDiabetes mellitusmedicineAnimalsHumansPharmacologyTriglyceridebiologyFatty liverLipid metabolismmedicine.diseaseFatty LiverStearoyl-CoA DesaturaseEndocrinologyFatty acid desaturasechemistrybiology.proteinFatty Acids UnsaturatedSteatosisStearoyl-CoA DesaturaseFatty Liver AlcoholicTranscription FactorsCurrent drug metabolism
researchProduct

Non-alcoholic Wernicke's encephalopathy: From MRI findings of a case to differential diagnosis checklist

2018

Wernicke's encephalopathy is a serious neurological disorder secondary to thiamine deficiency in alcoholics. However, rarely it affects non-alcoholics. Here we present a case of Wernicke's encephalopathy in a non-alcoholic 56-year-old female, treated by endoscopic surgery for a duodenal ulcer two years before. She came to our attention for a sudden onset of a neurological syndrome characterized by visual deficits, diplopia, confusion, spatial disorientation and loss of short-term memory. An MRI scan showed the typical MRI findings of Wernicke's encephalopathy, which are discussed together with the possible differential diagnosis.

medicine.medical_specialtyDiffusion-weighted magnetic resonance imagingWernicke Encephalopathymedicine.diagnostic_testWernicke encephalopathybusiness.industryMetabolic brain diseaseMedicine (all)Magnetic resonance imagingNon alcoholicGeneral Medicinemedicine.diseaseDiffusion-Weighted Magnetic Resonance ImagingChecklistWernicke's encephalopathyMagnetic resonance imagingThiamine deficiencymedicineRadiologyDifferential diagnosisbusinessMri findings
researchProduct

Voluntary distance running prevents disease progression in mice with non-alcoholic fatty liver disease (NAFLD)

2019

medicine.medical_specialtyDistance runningbusiness.industryInternal medicineFatty liverDisease progressionmedicineNon alcoholicDiseasemedicine.diseasebusinessGastroenterology35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
researchProduct